You are here: Industry Insights > CRISPR Therapeutics

News List

Vertex, CRISPR Therapeutics’ sickle cell gene therapy wins PRIME designation pharmatimes
September 27, 2020
Vertex Pharmaceuticals and CRISPR Therapeutics have been awarded a Priority Medicines (PRIME) designation from the European Medicines Agency for their CRISPR/Cas9 gene therapy, designed to treat severe sickle cell disease (SCD).
CRISPR Therapeutics and Vertex Pharmaceuticals announce FDA RMAT designation granted to CTX001 to tr pharmaceutical-business-review
May 14, 2020
CRISPR Therapeutics and Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX001.
CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies b3cnewswire
January 23, 2019
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases....
CRISPR biotech Editas to lose CMO as it continues push for clinical trials fiercebiotech
August 29, 2018
Editas is now looking for a new CMO as it also plots its first clinical trials
CRISPR Therapeutics Plans to Treat First Patients for Beta Thalassemia in Europe biospace
April 17, 2018
CRISPR Therapeutics is all ready to begin treating patients in Europe using its CRISPR gene-editing tool.
CRISPR and Massachusetts General Hospital partner to develop T-cell therapies pharmaceutical-technology
August 25, 2017
CRISPR Therapeutics has entered a new research collaboration and licence option agreement with Massachusetts General Hospital Cancer Centre (MGHCC) to develop new T-cell therapies for cancer.